A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ivermectin in asymptomatic and mild severity COVID-19 patients
Latest Information Update: 02 Feb 2023
At a glance
- Drugs Ivermectin (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Meditop Pharmaceutical
- 02 Feb 2023 Status changed from recruiting to discontinued.
- 11 Mar 2021 New trial record